NCT06396585

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction : a Prospective，Single-arm, Phase II Trial (TASTE Trial)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer

Conditions

• Immunotherapy Gastroesophageal Junction

Interventions

Type	Name	Description
DRUG	Tislelizumab	Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W
DRUG	Anlotinib	Participants will receive anlotinib,12mg, qd，d1-d14，Q3W
DRUG	Oxaliplatin	Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W
DRUG	Tegafur	Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W

Timeline

• Start date: 2024-08-01
• Primary completion: 2025-08-31
• Completion: 2026-08-31
• First posted: 2024-05-02
• Last updated: 2024-05-07

Locations

1 site across 1 country: China